Shire

Rani is a clinical-stage biotherapeutics company that enables the development of orally administered biologics to improve patient outcomes. They developed the RaniPill capsule, which is Rani's novel, proprietary, and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability, and bioavailability using the RaniPill capsule. Their development efforts have enabled them to construct an extensive intellectual property portfolio that they believe provides patients with a competitive advantage.

Dyax Corp. (Dyax) is a biopharmaceutical company focused on the discovery, development and commercialization of biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. The Company's lead product, DX-88, has been approved under the brand name KALBITOR (ecallantide) by the United States Food and Drug Administration (FDA) for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. The Company commercializes KALBITOR on its own in the United States. In addition to its approved commercial use for HAE in the United States, the Company is also developing DX-88 through collaborations in other indications. These include use of DX-88 for the reduction of blood loss during surgery in collaboration with Cubist Pharmaceuticals (Cubist), and for treatment of retinal diseases in collaboration with Fovea Pharmaceuticals (Fovea), which was acquired by sanofi-aventis during the year ended December 31, 2009.

Foresight Biotherapeutics is a clinical-stage drug development company pioneering novel therapies designed to address significant unmet needs in ophthalmology and otolaryngology. Foresight’s platform Povidone-Iodine (PVP-I) technology represents an important breakthrough in the treatment of ocular and otic inflammation including bacterial, viral and fungal infections. This platform enables PVP-I, a well-characterized broad spectrum antiseptic with no known microbial resistance, to be formulated in combination with a range of anti-inflammatory agents.

Meritage Pharma, Inc. develops prescription products for the treatment of gastrointestinal and atopic diseases. It offers budesonide, an active pharmaceutical ingredient and a glucocorticoid steroid for products that treat pediatric asthma, allergic rhinitis, and Crohn’s disease; and oral budesonide suspension, an oral formulation of budesonide for the potential treatment of adolescents and young adults with eosinophilic esophagitis, an allergic inflammation of the gastrointestinal tract. Meritage Pharma, Inc. was founded in 2008 and is based in San Diego, California.

At NPS Pharma, the most important thing they make is a difference in the lives of patients with rare diseases. People living with rare diseases have incredible courage. They have to, because they have few, if any, treatment options and are often overlooked because of the rarity of their disorders. Globally, there are approximately 7,000 rare disease and treatments exist for less than 500 of them. They can do better than this. They must do better than this. Their sole focus at NPS Pharma is rare diseases, and they are building a global pipeline of first-in- or best-in-disease therapies. Patients are at the center of everything they do. Each of us brings a personal passion to fulfilling their mission: To pioneer and deliver innovative therapies that transform the lives of patients with rare diseases worldwide. Their values and culture are the most important drivers of their success and will support us in achieving their vision of creating a world where every person living with a rare disease has a therapy. Integrity, respect, excellence, personal ownership, teamwork, entrepreneurial spirit and fun are the values that guide their work each day and what they expect from each other. They are the fabric of the NPS Pharma culture. They develop therapies for patients with significant unmet medical needs. In 2013, they launched their first product in the U.S. called Gattex® (teduglutide [rDNA origin]) for injection, which was also approved in Europe where they are launching it this year in select countries under the trade name Revestive®. NPS Pharma is currently conducting a global registration study for teduglutide in pediatric patients, because children have considerable, unique needs. NPS Pharma is also developing rhPTH [1-84], an investigational medicine being studied for the treatment for Hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of parathyroid hormone. Hypoparathyroidism is the only classic endocrine disorder without a parathyroid hormone replacement therapy. Their Biologics License Application is currently under FDA review and they are planning to file a European Marketing Authorization Application for rhPTH[1-84] this year. Their lead pipeline candidate is NPSP795, a small molecule being developed for the treatment of Autosomal Dominant Hypocalcemia or ADH. There is no approved therapy for this ultra-rare, life-long genetic disorder that affects both adults and children. They have a Phase 2a proof-of-concept study underway to evaluate NPSP795 for the treatment of adults with ADH. Today, NPS Pharma is a global rare disease company with approximately 300 employees and operations in the U.S., Canada, Europe, Latin America and Japan. They are passionate about transforming the lives of patients with rare diseases through science. Every day, they connect with people living with rare diseases. Every day, they connect with physicians, researchers, universities, policy makers and companies throughout the globe working in rare diseases. Together they can make a difference.

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Lumena Pharmaceuticals is developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package for a compound at this stage in development, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease. While Lumena’s primary focus is to develop novel treatments for patients with rare liver diseases, the company’s therapeutic approach also has promising potential in the treatment of metabolic diseases affecting the liver, a significant and growing health problem in children and adults.

Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company's drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex's platform of novel NMDAR modulators.

Fibrotech Therapeutics develops and offers novel drug candidates for the treatment of fibrosis in chronic conditions. It develops drugs for kidney diseases, diabetics, heart failure, pulmonary fibrosis, and arthritis. Founded in 2006, Fibrotech Therapeutics is based in Wonga Park, Australia.

Proclara Biosciences, Inc. develops fusion-protein drug candidates or therapies for the treatment of chronic neurodegenerative diseases, amyloidoses, Alzheimer’s and Parkinson’s diseases, multiple orphan indications, and other protein misfolding diseases in patients. It was formerly known as NeuroPhage Pharmaceuticals, Inc., and changed its name to Proclara Biosciences, Inc. in September 2016. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

ViroPharma Incorporated, a biopharmaceutical company, engages in the development and commercialization of products that address serious diseases, with a focus on products used by physician specialists or in hospital settings. The company has two marketed products, and three development programs. The company markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is a potent antibiotic approved by the U.S. Food and Drug Administration, or the FDA, to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection (CDI), or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.

Proclara Biosciences, Inc. develops fusion-protein drug candidates or therapies for the treatment of chronic neurodegenerative diseases, amyloidoses, Alzheimer’s and Parkinson’s diseases, multiple orphan indications, and other protein misfolding diseases in patients. It was formerly known as NeuroPhage Pharmaceuticals, Inc., and changed its name to Proclara Biosciences, Inc. in September 2016. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

SARcode Corporation is a private San Francisco based biopharmaceutical company engaged in the development of a novel class of small molecule lymphocyte function-associated antigen-1 (LFA-1; CD11a/CD18; αLβ2) antagonists as a topical agent for the treatment of significant unmet medical needs in ophthalmology, dermatology and other inflammatory diseases.

Premacure develops and commercializes insulin-like growth factor I (IGF-I) for unmet medical needs for the neonate. It develops IGF-I together with or without its IGFBP-3 natural binding protein for the prevention of complications of preterm birth.

ArmaGen is a developer of therapies designed to address neurological complications. The company's pipeline of innovative therapies penetrate the blood-brain barrier to treat neurological complications of many diseases, including lysosomal storage disorders (LSDs), Alzheimer's and Parkinson's, enabling patients suffering from neurodegenerative disorders to get improved treatment.

Promedior is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and fibrotic diseases Promedior has developed a novel drug discovery platform to regulate the monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases. By specifically targeting these cells at the site of injury, Promedior is able to treat the source of aberrant immune system responses, promote tissue healing and resolution, and greatly reduce the risk of systemic side effects inherent in current therapeutic approaches. Promedior is developing drugs to address the most severe and difficult-to-treat fibrotic and inflammatory conditions of the eye, lung and kidney such as glaucoma, age-related macular degeneration, diabetic retinopathy and dry eye disease; pulmonary fibrosis, scleroderma and COPD; and acute and chronic nephropathy.

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Enterome’s OncoMimic technology allows the overcoming of immune tolerance against cancer cells, with broad applicability against solid tumor via an off-the-shelf, easy to manufacture technology. Enterome’s potentially first-in-class small protein and peptide drug candidates modulate the immune system by closely mimicking the structure, effect or actions of Tumor Associated Antigens to induce a potent, endogenous CD8 T cell response. The company’s most advanced programs are in Phase 2 clinical trials in hard-to-treat tumors such as glioblastoma, adrenal malignancies and colorectal cancer.

Ferrokin Biosciences Inc. develops and markets medical devices. The company offers iron chelator for the treatment of iron-overload in patients with transfusion-dependent hereditary and acquired refractory anemias. The company is based in San Carlos, California.

Proclara Biosciences, Inc. develops fusion-protein drug candidates or therapies for the treatment of chronic neurodegenerative diseases, amyloidoses, Alzheimer’s and Parkinson’s diseases, multiple orphan indications, and other protein misfolding diseases in patients. It was formerly known as NeuroPhage Pharmaceuticals, Inc., and changed its name to Proclara Biosciences, Inc. in September 2016. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Advanced BioHealing is an industry leader in the science of regenerative medicine. The Company is focused on the commercialization of cell-based and tissue-engineered products. It currently markets the FDA-approved product Dermagraft®, for diabetic foot ulcers. Additionally, the Company's development pipeline includes a next-generation bioengineered tissue product which is in clinical trials. ABH is a privately held company with research & development offices in New York, NY and manufacturing operations in La Jolla, CA.

Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease. Prexa’s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa’s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa’s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.

Proclara Biosciences, Inc. develops fusion-protein drug candidates or therapies for the treatment of chronic neurodegenerative diseases, amyloidoses, Alzheimer’s and Parkinson’s diseases, multiple orphan indications, and other protein misfolding diseases in patients. It was formerly known as NeuroPhage Pharmaceuticals, Inc., and changed its name to Proclara Biosciences, Inc. in September 2016. The company was founded in 2006 and is headquartered in Cambridge, Massachusetts.

Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient's refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.

- Jerini was founded in 1994 as a spin-off from the Medical Faculty (Charité) Humboldt University Berlin to commercialize the SPOT™ technology. The evolving SPOT™ platform was marketed as fee for service projects to pharmaceutical and biotech companies (1995 to 1999). The revenues generated supported the expansion of the company and its technology development. At this stage no venture capital was raised. Due to the expanding applications of its technology platform in drug discovery and proteomics Jerini began its transformation into a drug discovery company. - To support and accelerate the drug discovery transition Jerini raised Euro 4.6 million in January 2000 in a first financing round that included local investors IBB-Bet. GmbH, bmp AG and tbg. In 2001 the company converted to an AG (joint-stock company) and closed its second, private financing round raising Euro 20 million in November 2001. The investors in this round included an international group represented by TVM, 3i, Polytechnos and Sanders Morris and Harris. - In 2000 Jerini started creating the medicinal chemistry platform PepMed™ focusing on the identification of peptide lead structures addressing difficult protein targets and their subsequent systematic transformation into drug-like molecules. - In December 2001 Jerini started its first clinical trials with Icatibant, a peptidomimetic bradykinin receptor antagonist for the indication defined as end-stage liver cirrhosis.

New River Pharmaceuticals Inc. ("NRPH") is a specialty pharmaceutical company developing novel pharmaceuticals that are generational improvements of widely-prescribed drugs in large and growing markets. We are developing new molecular entities that are derivatives of public domain actives using our proprietary Carrierwave™ technology.

BIKAM Pharmaceuticals is a drug discovery company focused on the discovery and development of novel drugs for degenerative diseases. It discovers and develops pharmacologic chaperones for misfolded proteins within the retina that lead to serious retinal degenerative disease and blindness, including retinitis pigmentosa and dry age-related macular degeneration. BIKAM Pharmaceuticals was founded in 2007 and is based in Cambridge, Massachusetts.